Malignant neoplasm of breast
Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader
Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations
Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights
ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines
RadNet Acquires See-Mode to Expand AI Ultrasound for Breast and Thyroid Cancer Diagnostics
RadNet; See-Mode Technologies; AI ultrasound; breast cancer; thyroid cancer; DeepHealth; diagnostic imaging; FDA approval; workflow efficiency; acquisition
AstraZeneca Details Its Oral SERD ‘Switching’ Regimen Amid Feasibility Questions
AstraZeneca; oral SERD; camizestrant; breast cancer; ESR1 mutation; SERENA-6 trial; CDK4/6 inhibitor; disease progression; ASCO 2025; treatment resistance
Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC
Emi-Le, Mersana, VTCN1 gene, Antibody-Drug Conjugates, emiltatug ledadotin, Malignant neoplasm of breast, 55%
AstraZeneca unfolds first DTC TV ad for breast cancer med Truqap
Truqap, AstraZeneca, Television, Faslodex, Malignant neoplasm of breast
AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data
Cancer research, AACR 2025, Marengo Therapeutics, BriaCell, oncology advancements, colorectal cancer, breast cancer, immunotherapy
Lilly continues full-court press against breast cancer with women’s March Madness event sponsorships
Eli Lilly, Woman, Madness, Malignant neoplasm of breast, Event, Awareness, Basketball game
Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study
Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche
Enhertu Secures 7th FDA Approval for Expanded Use in HER2-Low and HER2-Ultralow Breast Cancer
Enhertu, FDA Approval, HER2-Low, HER2-Ultralow, Breast Cancer, AstraZeneca, Daiichi Sankyo